RE:Still a scrap.The study's outcome represents a noteworthy milestone, with blarcamesine being among the first drugs to exhibit efficacy on biomarkers of neurodegeneration.
Moreover, blarcamesine demonstrated a strong anti-amyloid effect, as indicated by a significant increase in the plasma Aβ42/40 ratio, a validated biomarker of amyloid beta pathology. MRI scans revealed a notable reduction in brain volume loss across various brain regions, including the whole brain.